Theorem CR talks about life after spin out at DIA 2011

By Gareth Macdonald

- Last updated on GMT

Rebranded CRO Theorem Clinical Research talks about life as an independent organisation and the current vogue for private equity investments.

Earlier​ this year US pharmacy distribution group Omnicare Inc sold its contract research arm to private equity investor Nautic Partners.

CEO James Pusey told Outsourcing-pharma.com about developments since the acquisition at DIA 2011, explaining that one of the benefits of independence is accelerated decision making, especially in relation to technology.

Historically we were only investing about three of four hundred thousand dollars a year in new technologies, which was not enough…now we have surpassed $3m per year​.”

Dr Pusey added that the Theorem is also able to react more quickly to opportunities, citing intervention medical device trials as a growing area of demand for the firm.

He also predicted that the wave of private equity investments in contract research organisation (CRO) will continue as the pharmaceutical industry continues to evolve.

The thing about private equity is that it tends to invest for the long term. It tends to think ‘how can we benefit from a financial return in a changing market? And how can we rapidly support a game changing situation?”

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers